Adrian Newman-Tancredi, PhD, DSc, will present on novel antidepressant drugs at the forthcoming European College of Neuropsychopharmacology (ECNP) Congress to be held on 7-10 September in Copenhagen, Denmark. Together with Prof. Luc Zimmer of the Cermep Brain Imaging center (Lyon, France), Dr. Newman-Tancredi will lead a 'Brainstorming Session' on rapid-acting antidepressant drugs (RAADs) such as ketamine. Drug discovery efforts at Neurolixis have identified novel 'biased agonists', e.g. NLX-101, that show striking antidepressant activity in animal models. Moreover, the session will discuss how brain imaging technologies, including PET, fMRI and fUS, can help investigate brain region-specific effects of novel antidepressants.
Brainstorming session BS.02
Title: "The search for safe and rapid-acting antidepressants in the post-ketamine era: challenges for biased agonists"
Date: Sunday 9 September at 7h45 am, Room B2.
Chair: Kamilla Miskowiak, Professor of Cognitive Neuropsychiatry at the University of Copenhagen.
For full details of the session see the meeting website.